ETD001 single dose ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 299 | Cystic fibrosis | 1 |
299. Cystic fibrosis
Clinical trials : 1,695 / Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04926701 (ClinicalTrials.gov) | June 11, 2021 | 10/6/2021 | A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD001 in Healthy Subjects | A First in Human Randomised, Double Blind, Placebo-controlled, Two-part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses (SAD and MAD) of Inhaled ETD001 in Healthy Male and Female Subjects | Cystic Fibrosis | Drug: ETD001 single dose;Drug: Placebo single dose;Drug: ETD001 multiple twice daily doses;Drug: Placebo multiple twice daily doses;Drug: ETD001 multiple once daily doses;Drug: Placebo multiple once daily doses | Enterprise Therapeutics Ltd | NULL | Completed | 18 Years | 50 Years | All | 98 | Phase 1 | United Kingdom |